Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/5/2009

ongoing discussions with regulatory authorities and the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential inability to reach final agreement with regulatory agencies on the use of a surrogate endpoint and phase 3 trial design for Amigal; the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier clinical trials may not be predictive of future results. Additionally, with respect to statements regarding projections of the Company's cash position and expected use of cash during 2009, actual results may differ based on market factors, the company's ability to execute its operational and budget plans, and its achievement of milestones and receipt of milestone payments from Shire. Additionally, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Table 1
                             Amicus Therapeutics, Inc.
                           (a development stage company)
                       Consolidated Statements of Operations
   
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
5. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
6. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
7. Amicus Therapeutics Opens Research Facility in San Diego
8. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
9. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
10. Amicus Therapeutics Announces First Quarter 2008 Financial Results
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Sterlitech is proud to announce that it ... stable of products . These additional products increase ... membrane filters with surface charges. , “We ... our membrane process testing equipment, and correspondingly, a wider ... explains Sterlitech President Mark Spatz. “The addition of ...
(Date:8/28/2014)... A new market research report detailing ... from Strategic Consulting, Inc., the leading information resource ... Review, Fourth Edition: Global Review of Microbiology Testing ... compares microbiology test volumes, market values and methods ... and forecasts future volumes and market values through ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Whitehouse Laboratories ... long term partnership with PTI Inspection Systems ... with state of the art leak testing method development ... art instruments currently available. As part of this agreement, ... High Voltage Leak Detection Instrument developed and manufactured ...
(Date:8/27/2014)... 2014 In 2013, Lawrence ... Livermore National Security LLC (LLNS), was awarded ... a state-of-the-art laser system for the European Union's ... construction in the Czech Republic. , When commissioned ... called the " High repetition-rate Advanced Petawatt Laser ...
Breaking Biology Technology:Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... N.C., Sept. 2 Sicel Technologies, Inc., announced ... into involuntary bankruptcy. Effective August 31, 2010, Paul ... Director of the company. Currently, Sicel,s operations are ... furloughed have returned to work.Media Contact: Lisa P. ...
... EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board -- VIENNA, Austria, September 2, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... and the Wyss Institute for Biologically Inspired Engineering ... one of the most microscopic forms of lifebacteria. ... Nature . In studying the development of ... populations most adept at withstanding doses of antibiotics are ...
Cached Biology Technology:EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 2EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 3EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 4EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 5EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 6EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board 7Charitable behavior found in bacteria 2
(Date:8/28/2014)... Society of America (ESA) is pleased to announce the ... of the Society. Honorary Membership acknowledges those who have ... involvement in the affairs of the Society that has ... selected by the ESA Governing Board and then voted ... honored at the Awards Ceremony at Entomology 2014, ESA,s ...
(Date:8/28/2014)... available in German . ... its name to a striking pattern of blue stripes alternating ... reflective silvery cells, and yellow cells emerge during growth in ... a multilayered mosaic to compose the characteristic colour pattern. ... have to interact to form proper stripes, the embryonic origin ...
(Date:8/28/2014)... Mayo Clinic researcher and his collaborators have developed an ... the process of re-engineering cells for biomedical investigation. CellNet ... methods to aid stem cell engineering. Details of CellNet ... in two back-to-back papers in the journal Cell ... of uses for all types of cell-based investigations and ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3New tool aids stem cell engineering for medical research 2
... Could combustion without flames be used to build industrial ... efficient than current models and produce almost no polluting ... answer in the current issue of the Inderscience publication, ... Sassi of The Petroleum Institute in Abu Dabi (United ...
... child go on to have fewer children than women who ... a study from the Norwegian Institute of Public Health (NIPH) ... Medical Birth Registry and the University of Bergen have collected ... until 2003. This covers nearly 600 000 births, so the ...
... rain forest peoples in Latin America are preparing themselves ... climate issues. A major landmark in preparing for the ... Climate Change will take place from April 1-4 in ... experts will be participating in the workshop "Climate Change ...
Cached Biology News:Fire without smoke 2Fewer babies born after Caesarean delivery 2International workshop to address capacity building for rainforest leaders 2International workshop to address capacity building for rainforest leaders 3
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: